Taiho Oncology, Inc.
A purpose-driven scientific organization committed to delivering treatments that make a real difference in the lives of people living with cancer.
Our mission
We are a purpose-driven scientific organization. The work is to translate science into therapies for the people who need them — and to publish the trial data on schedule, even when it is inconvenient.
The next generation of agents is in the hands of clinicians, scientists, and operators who report to one another before they report to the market.
A family in the waiting room — real faces, real light, real hands.
For patients
Patient and caregiver perspectives shape every program — not as a focus group at the end, but as participants from the first protocol draft forward.
A scientist at the bench — daylight from a high window, warm tones.
For science
Scientific collaboration is the discipline. Our scientists publish, partner, and translate — small teams with the bench knowledge to push the next generation of agents forward.
Development pipeline
As of Q2 2026
Metastatic colorectal cancer
Oral nucleoside analog
Advanced gastric cancer
Selective MEK inhibitor
Pancreatic ductal adenocarcinoma
Antibody-drug conjugate
Hematologic malignancies
Bispecific T-cell engager
Solid tumors (basket trial)
KRAS G12C inhibitor
Collaboration
We partner with academic centers, biotech founders, and patient advocacy groups. The premise is simple: the science compounds when the people doing it are talking to each other.
